DOW JONES NEWSWIRES -- Andrew Bodnar, a former executive of Bristol-Myers Squibb Co. (BMY), pleaded guilty Monday to a charge related to his role in a patent deal the drug maker struck to keep a generic competitor to its popular blood-thinning drug, Plavix, off the market.
